Trial · NCT07890987
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in SMAS/Fibromuscular Layer Firmness | Baseline and Day 180 | Difference between baseline and Day 180 in SMAS/fibromuscular layer stiffness measured using Shear-Wave Elastography. |
| Secondary | Change From Baseline in Facial Soft-Tissue Displacement Measured by Vectra 3D Imaging | Baseline, Day 90, and Day 180 | Facial tissue displacement, in millimeters (mm), measured by three-dimensional imaging with the Vectra 3D system (Canfield Scientific), compared between the single-depth (1.5 mm) side and the multi-depth side. Time Frame : Baseline, Day 90, and Day 180 |
| Secondary | changes in dermal thickness | Baseline and Day 180 | Histologic evaluation of treatment-induced change in dermal thickness. Unit of Measure: millimeters (mm) |
| Secondary | Change in Skin elasticity measured by ElastiMeter | Baseline, Day 90, and Day 180 | Instant skin elasticity (ISE), expressed in newtons per meter (N/m), measured by indentation with the ElastiMeter (Delfin Technologies) on each side of the face. Higher values indicate greater tissue resistance to indentation. Compared between the single-depth (1.5 mm) side and the multi-depth side. |
| Secondary | Change in collagen type I regeneration | Baseline and Day 180 | Histologic evaluation of collagen type I regeneration measured by immunohistochemistry, expressed as the percentage of collagen-I-positive area relative to total tissue area. Unit of Measure: % positive area |
| Secondary | Change in collagen type III regeneration | Baseline and Day 180 | Histologic evaluation of collagen type III regeneration measured by immunohistochemistry, expressed as the percentage of collagen-III-positive area relative to total tissue area. Unit of Measure: % positive area |
| Secondary | Change in elastin regeneration | Baseline and Day 180 | Histologic evaluation of elastin regeneration measured by elastin-specific staining/immunohistochemistry, expressed as the percentage of elastin-positive area relative to total tissue area. Unit of Measure: % positive area |
| Secondary | Change in proteoglycan content | Baseline and Day 180 | Histologic evaluation of proteoglycan content measured by Alcian Blue/Safranin O staining or proteoglycan-specific immunohistochemistry, expressed as the percentage of stained area relative to total tissue area. Unit of Measure: % positive area |
| Secondary | Change in collagen fiber alignment | baseline and day 180 | image-analysis-derived collagen fiber coherence/alignment, expressed as an orientation index ranging from 0 (random alignment) to 1 (perfect alignment). Unit of Measure: orientation index (0-1), dimensionless |
| Secondary | Change in elastin fiber alignment | Baseline and day 180 | Image-analysis-derived elastin fiber coherence/alignment, expressed as an orientation index ranging from 0 (random alignment) to 1 (perfect alignment). Unit of Measure: orientation index (0-1), dimensionless |
| Secondary | Change in MMP-1 expression | Baseline and day 180 | Histologic evaluation of MMP-1 expression measured by immunohistochemistry, expressed as the percentage of MMP-1-positive cells relative to total cells. Unit of Measure: % positive cells |
| Secondary | Change in MMP-3 expression | Baseline and Day 180 | Histologic evaluation of MMP-3 expression measured by immunohistochemistry, expressed as the percentage of MMP-3-positive cells relative to total cells. Unit of Measure: % positive cells |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07890987/registered